19. Neurogen Brain and Spine Institute. Stem cell therapy in Duchenne
muscular dystrophy. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National
Library of Medicine (US). 2000- [cited 2016Jul]. Available from:
https://clinicaltrials.gov/ct2/show/NCT02241434
NLM
Identifier:
NCT02241434.
20. University of Gaziantep; Alper Dai. Efficacy of stem cell therapy in
ambulatory and non-ambulatory children with Duchenne muscular dystrophy -
phase 1-2. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of
Medicine
(US).
2000-
[cited
2016Jul].
Available
from:
https://clinicaltrials.gov/ct2/show/NCT02484560
NLM
Identifier:
NCT02484560.
21. Chaitanya Hospital, Pune; Sachin Jamadar. Study safety and efficacy of
bone marrow derived autologous cells for the treatment of muscular dystrophy.
In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine
(US).
2000-
[cited
2016Jul].
Available
from:
https://clinicaltrials.gov/ct2/show/NCT01834066
NLM
Identifier:
NCT01834066.
Tài liệu tham khảo bổ sung
Markert CD, Atala A, Cann JK, et al., “Mesenchymal stem cells: emerging
therapy for Duchenne muscular dystrophy.” PM R. 2009 Jun; 1(6): 547-59. doi:
10.1016/j.pmrj.2009.02.013.
Chương 2
1. Creagan ET, Moertel CG, O’Fallon JR, et al. Failure of high-dose vitamin
C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled
trial. N Engl J Med. 1979 Sep 27; 301(13): 687-90.
2. Hoffer LJ. Proof versus plausibility: rules of engagement for the struggle
to evaluate alternative cancer therapies. CMAJ. 2001; 164(3): 351-3.
3. Padayatty SJ, Levine M. New insights into the physiology and
pharmacology of vitamin C. CMAJ. 2001; 164(3): 353-5.
4. Riordan NH, Riordan HD, inventors; The Center for the Improvement of
Human Functioning Int’l, Inc., assignee. Therapeutic method for the treatment of
